Skip to main content
Premium Trial:

Request an Annual Quote

Former NCI Bioinformatics Head Joins Genaissance

Premium

NEW HAVEN, Conn.--Genaissance Pharmaceuticals, a company that exploits gene variation for the pharmaceutical industry, named Joel Claiborne Stephens as director of population genomics. Stephens, who has headed the bioinformatics group at the US National Cancer Institute since 1990, will direct the application of gene haplotypes for more effective clinical trails and the enhancement of drugs in the market, Genaissance said.

Stephens, 45, is a leading investigator in the application of haplotypes to predict clinical points. At the cancer institute, Stephens was part of an AIDs-related program utilizing population genetic strategies to trace HIV resistance in selected patient groups. At Genaissance he will continue his previous work in bioinformatics and algorithm models for the analysis of gene variation.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.